tbuckley/cabot-search huggingface dataset:
P-145 CT-based texture analysis using radiomics for hepatic sinusoidal obstruction syndrome (HSOS) in colorectal cancer patients treated with oxaliplatin containing chemotherapy
Authors: K. Kawaguchi, D. Manaka, S. Konishi, T. Ota, Y. Ikeda, R. Kudo, H. An, N. Sasaki, S. Hamasu, R. Nishitai, Y. Mori, N. Inamoto, K. Shibamoto, A. Ogata, T. Yamaoka, Y. Himoto
Journal: Annals of Oncology (2020)
Artificial intelligence to improve back pain outcomes and lessons learnt from clinical classification approaches: three systematic reviews
Authors: Scott D. Tagliaferri, Maia Angelova, Xiaohui Zhao, Patrick J. Owen, Clint T. Miller, Tim Wilkin, Daniel L. Belavy
Journal: npj Digital Medicine (2020)

Artificial intelligence and machine learning (AI/ML) could enhance the ability to detect patterns of clinical characteristics in low-back pain (LBP) and guide treatment. We conducted three systematic reviews to address the following aims: (a) review the status of AI/ML research in LBP, (b) compare its status to that of two established LBP classification systems (STarT Back, McKenzie). AI/ML in LBP is in its infancy: 45 of 48 studies assessed sample sizes <1000 people, 19 of 48 studies used ≤5 parameters in models, 13 of 48 studies applied multiple models and attained high accuracy, 25 of 48 studies assessed the binary classification of LBP versus no-LBP only. Beyond the 48 studies using AI/ML for LBP classification, no studies examined use of AI/ML in prognosis prediction of specific sub-groups, and AI/ML techniques are yet to be implemented in guiding LBP treatment. In contrast, the STarT Back tool has been assessed for internal consistency, test-retest reliability, validity, pain and disability prognosis, and influence on pain and disability treatment outcomes. McKenzie has been assessed for inter- and intra-tester reliability, prognosis, and impact on pain and disability outcomes relative to other treatments. For AI/ML methods to contribute to the refinement of LBP (sub-)classification and guide treatment allocation, large data sets containing known and exploratory clinical features should be examined. There is also a need to establish reliability, validity, and prognostic capacity of AI/ML techniques in LBP as well as its ability to inform treatment allocation for improved patient outcomes and/or reduced healthcare costs.
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
Authors: Onima Chowdhury, Jennifer O’Sullivan, Nikolaos Barkas, Guanlin Wang, Gemma Buck, Angela Hamblin, Ayalew Tefferi, Haifa K. Al-Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qian Jiang, Jean-Jacques Kiladjian, Ruben Mesa, Francesco Passamonti, Vincent Ribrag, Gary Schiller, Alessandro M. Vannucchi, Daobin Zhou, Mary Frances McMullin, Jianhua Zhong, Robert Peter Gale, Adam J. Mead, John Catalano, William Stevenson, Günther Gastl, Werner Linkesch, Jan Van Droogenbroeck, Philippe Mineur, Vikas Gupta, Andrew Turner, Thomas Nevill, Jianyong Li, Zhixiang Shen, Ting Liu, Dominique Bordessoule, Shanti Natarajan-Amé, Christian Recher, Jean Loup Demory, Richard Schlenk, Martin Griesshammer, Mario Cazzola, Giuseppe Saglio, Giorgina Specchia, Alessandro Rambaldi, Fabrizio Pane, Sonja Zweegman, Peter te Boekhorst, Reinier Raymakers, Kudrat Abdulkadyrov, Manana Sokolova, Galina Salogub, Andrey Zaritskiy, Francisco Cervantes, Juan Carlos Hernández Boluda, Emilio Ojeda, Daniel Tesfa, Lars Nilsson, Mark Drummond, John Reilly, Claire Harrison, Dragana Milojkovic, Candido Rivera, Emmanuel Besa, H. Joachim Deeg, John Mascarenhas, Josef Prchal, Ramon Tiu, Moshe Talpaz, Jen Chin Wang, Raajit Rampal, Damiano Rondelli, Kelly McCaul, Randall Brown, Norio Komatsu, Kazuma Ohyashiki, Kiyoshi Ando, Hiroshi Kawabata, Katsuto Takenaka, Tomoko Hata, James Vardiman
Journal: Leukemia (2020)
P-241 First- and second-line treatment with tyrosine kinase inhibitors after chemoembolization in intermediate-stage hepatocellular carcinoma patients
Authors: E. Manthopoulou, E. Michalopoulou, D. Dimitroulopoulos, D. Kypreos, D. Katsinelos, I. Marakis, K. Tsamakidis, G. Sachtouris, X. Tsamakidis
Journal: Annals of Oncology (2020)
Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations
Authors: Christopher A. Eide, Stephen E Kurtz, Andy Kaempf, Andrew Park, Angela Rofelty, Beth Wilmot, Daniel Bottomly, Shannon K. McWeeney, Cristina E. Tognon, Motomi Mori, Jeffrey W. Tyner, Brian J. Druker
Journal: Blood (2017)
Conversion of Urine Protein–Creatinine Ratio or Urine Dipstick Protein to Urine Albumin–Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis
Authors: Keiichi Sumida, Girish N. Nadkarni, Morgan E. Grams, Yingying Sang, Shoshana H. Ballew, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Nigel Brunskill, Steve J. Chadban, Alex R. Chang, Massimo Cirillo, Kenn B. Daratha, Ron T. Gansevoort, Amit X. Garg, Licia Iacoviello, Takamasa Kayama, Tsuneo Konta, Csaba P. Kovesdy, James Lash, Brian J. Lee, Rupert W. Major, Marie Metzger, Katsuyuki Miura, David M.J. Naimark, Robert G. Nelson, Simon Sawhney, Nikita Stempniewicz, Mila Tang, Raymond R. Townsend, Jamie P. Traynor, José M. Valdivielso, Jack Wetzels, Kevan R. Polkinghorne, Hiddo J.L. Heerspink
Journal: Annals of Internal Medicine (2020)

Background: Although measuring albuminuria is the preferred method for defining and staging chronic kidney disease (CKD), total urine protein or dipstick protein is often measured instead. Objective: To develop equations for converting urine protein–creatinine ratio (PCR) and dipstick protein to urine albumin–creatinine ratio (ACR) and to test their diagnostic accuracy in CKD screening and staging. Design: Individual participant–based meta-analysis. Setting: 12 research and 21 clinical cohorts. Participants: 919 383 adults with same-day measures of ACR and PCR or dipstick protein. Measurements: Equations to convert urine PCR and dipstick protein to ACR were developed and tested for purposes of CKD screening (ACR ≥30 mg/g) and staging (stage A2: ACR of 30 to 299 mg/g; stage A3: ACR ≥300 mg/g). Results: Median ACR was 14 mg/g (25th to 75th percentile of cohorts, 5 to 25 mg/g). The association between PCR and ACR was inconsistent for PCR values less than 50 mg/g. For higher PCR values, the PCR conversion equations demonstrated moderate sensitivity (91%, 75%, and 87%) and specificity (87%, 89%, and 98%) for screening (ACR >30 mg/g) and classification into stages A2 and A3, respectively. Urine dipstick categories of trace or greater, trace to +, and ++ for screening for ACR values greater than 30 mg/g and classification into stages A2 and A3, respectively, had moderate sensitivity (62%, 36%, and 78%) and high specificity (88%, 88%, and 98%). For individual risk prediction, the estimated 2-year 4-variable kidney failure risk equation using predicted ACR from PCR had discrimination similar to that of using observed ACR. Limitation: Diverse methods of ACR and PCR quantification were used; measurements were not always performed in the same urine sample. Conclusion: Urine ACR is the preferred measure of albuminuria; however, if ACR is not available, predicted ACR from PCR or urine dipstick protein may help in CKD screening, staging, and prognosis. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases and National Kidney Foundation.
Abstract 14155: Effect of Chronic Calcium-Channel Blocker Therapy After Coronary Artery Bypass With the Radial Artery: Insights From the RADIAL Database
Authors: Mario F Gaudino, Umberto Benedetto, Stephen Fremes, David L Hare, Philip Hayward, Neil Moat, Giuseppe Nasso, Miodrag Peric, Kyung J Yoo, Giuseppe Speziale, David Taggart
Journal: Circulation (2018)

Aim: To evaluate if chronic calcium-channel blocker therapy (CCB) influences mid-term clinical and angiographic outcomes of radial artery (RA) grafts used for coronary bypass surgery (CABG). Method...
P-43 Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study
Authors: F. Longo, M. Jorge Fernandez, R. Yaya Tur, A. Fernández Montes, N. Martínez Lago, E. Brozos Vázquez, J. Aparicio Urtasun, G. Quintero Aldana, E. Ceballos Barbancho, E. Buxó Orra, A. Lopez Muñoz, M. Pellón Augusto, R. Molina Villaverde, L. Díaz-Paniagua, P. Cerdà Serdà, P. López-Leiva, A. Martín-Carnicero, A. Cousillas Castiñeiras, L. París Bouzas, B. García Paredes, C. Romero Reinoso, M. Ortega Sedano
Journal: Annals of Oncology (2020)
Abstract 15323: Sex-Specific Differences in the Association Between Serum Uric Acid and the Incidence of Cardiovascular Events in the General Population
Authors: Yuuki Matsuura, Toshie Segawa, Fumitaka Tanaka, Ryosuke Komi, Kozo Tanno, Masaki Ohsawa, Yasuhiro Ishibashi, Shinichi Omama, Kiyomi Sakata, Kuniaki Ogasawara, Akira Okayama, Motoyuki Nakamura
Journal: Circulation (2017)

Background: The role of serum uric acid (SUA) as an independent predictor of cardiovascular (CV) events in the general population is uncertain. It has been argued that previous studies may not have...
COVID-19 and the Ophthalmology Match
Authors: David A. Quillen, R. Michael Siatkowski, Steven Feldon
Journal: Ophthalmology (2020)

The coronavirus disease 2019 (COVID-19) pandemic has impacted ophthalmology and medical education profoundly. In an effort to reduce the transmission of severe acute respiratory syndrome coronavirus 2, the American Academy of Ophthalmology issued a statement on March 18, 2020, urging all ophthalmologists immediately to cease providing any treatment other than urgent or emergent care.1 This recommendation—endorsed by every major ophthalmology organization in the United States—resulted in a 79% reduction in care, the highest decline of any medical or surgical discipline.
LBA-4 Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer
Authors: Y. Sunakawa, Y. Sakamoto, E. Inoue, R. Kawabata, A. Ishiguro, Y. Akamaru, Y. Kito, M. Takahashi, J. Matsuyama, H. Yabusaki, A. Makiyama, T. Suzuki, M. Tsuda, H. Yasui, N. Hirabayashi, A. Takeno, H. Kawakami, R. Matoba, K. Muro, T. Nakajima, W. Ichikawa, M. Fujii
Journal: Annals of Oncology (2020)
P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens
Authors: J. Tabernero, E. Elez Fernandez, F. Ghiringhelli, G. Folprecht, G. Curigliano, S. Siena, C. Cremolini, A. Sobrero, M. Kwiatek, S. Roselló Keränen, D. Ahn, C. Punt, D. Laurent, M. Ferrara, A. Pellacani, A. Capriati
Journal: Annals of Oncology (2020)
Alastair John Forrest
Authors: Sarah Forrest
Journal: BMJ (2020)

Alastair John Forrest was born in Palmerston North, New Zealand, to Gavin, a GP, and Joan Forrest. He qualified from the University of Otago, New Zealand, in 1965 before completing his house jobs in Auckland. From here he travelled to the UK as a ship’s doctor on an Anchor Butter boat, a story often shared in the years since, reflecting both his love of the sea as well as his unassuming nature. He subsequently worked in the US as an intern at Washington Hospital Center and then as a resident in psychiatry at Manhattan State Hospital.

Alastair travelled back to the UK to join the London Hospital psychiatry rotation and then the training schemes at St George’s Hospital. He became one of the youngest consultant psychiatrists on gaining his membership to the Royal College of Psychiatrists in 1974.

Alastair’s first consultant post was at Netherne Hospital in Surrey, where he worked for 15 years. This period covered the move away from inpatient to community care and lead up to the closure of the hospital, after nearly a century as one of the large psychiatric hospitals around London. It was here he …
PTH-115 Comparison of immunogenicity of biosimilar infliximab and originator infliximab in children with inflammatory bowel disease in real life setting
Authors: A Wahid, R Muhammed
Journal: Gut (2017)

Introduction  Biosimilar Infliximab has been licensed in the UK since 2015 for use in children with Inflammatory Bowel Disease (IBD). The aim is to compare the immunogenicity and response to treatment and factors associated with it in patients with IBD on treatment with originator and biosimilar Infliximab.  Method  We included all patients with Crohn’s Disease (CD) and Ulcerative colitis (UC) who had anti-Infliximab antibodies measured between 2011–2016. Retrospective review of patient notes and laboratory results were conducted. Anti-Infliximab antibodies were requested by the clinician in charge based on clinical needs of the patients. Anti-Infliximab antibodies were measured using second generation ELISA test identifying both free and combined antibodies. Disease remission was assessed by Physician Global Assessment (PGA).  Results  In total 145 patients (124 with CD and 21 with UC) were included. 86 patients were on Originator Infliximab (80 with CD and 6 with UC) and 59 patients (44 with CD and 15 with UC) were on biosimilar Infliximab. Biosimilar Infliximab used was CT-P13 (Remsima and Inflectra). For children with Crohn’s disease median age, disease extent and the rate of perianal involvement were not different in patients receiving originator and biosimilar Infliximab. A similar proportion of patients with Crohn’s disease (70% in the originator group and 77% in the biosimilar group) developed anti-Infliximab antibodies. Detailed characteristics of these patients and their treatment are in Table 1. Comparison of the results of children with ulcerative colitis was limited by the small number of children receiving originator Infliximab.  Conclusion  Anti-Infliximab antibody formation occurs in a high proportion of patients receiving both originator and biosimilar Infliximab. Dose/frequency adjustment is needed for a good proportion of IBD patients on Infliximab treatment to achieve clinical remission. Rate of anti-Infliximab antibody formation and clinical remission are very similar in CD patients on originator and biosimilar Infliximab.  Disclosure of Interest  A. Wahid: None Declared, R Muhammed Conflict with: Abbvie, MSD, Conflict with: Abbvie, Pfizer, Dr Falk pharma, Conflict with: Tillotts pharma, Takeda pharmaceuticals
Extrapulmonary manifestations of COVID-19
Authors: Aakriti Gupta, Mahesh V. Madhavan, Kartik Sehgal, Nandini Nair, Shiwani Mahajan, Tejasav S. Sehrawat, Behnood Bikdeli, Neha Ahluwalia, John C. Ausiello, Elaine Y. Wan, Daniel E. Freedberg, Ajay J. Kirtane, Sahil A. Parikh, Mathew S. Maurer, Anna S. Nordvig, Domenico Accili, Joan M. Bathon, Sumit Mohan, Kenneth A. Bauer, Martin B. Leon, Harlan M. Krumholz, Nir Uriel, Mandeep R. Mehra, Mitchell S. V. Elkind, Gregg W. Stone, Allan Schwartz, David D. Ho, John P. Bilezikian, Donald W. Landry
Journal: Nature Medicine (2020)
The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis
Authors: Zhibin Yan, Dan Wang, Chunmei An, Hongjiao Xu, Qian Zhao, Ying Shi, Nazi Song, Bochuan Deng, Xiaomin Guo, Jing Rao, Lu Cheng, Bangzhi Zhang, Lingyun Mou, Wenle Yang, Xianxing Jiang, Junqiu Xie
Journal: Acta Pharmaceutica Sinica B (2020)

The antimicrobial peptide APKGVQGPNG (named YD), a natural peptide originating from Bacillus amyloliquefaciens CBSYD1, exhibited excellent antibacterial and antioxidant properties in vitro. These characteristics are closely related to inflammatory responses which is the central trigger for liver fibrosis. However, the therapeutic effects of YD against hepatic fibrosis and the underlying mechanisms are rarely studied. In this study, we show that YD improved liver function and inhibited the progression of liver fibrosis by measuring the serum transaminase activity and the expression of α-smooth muscle actin and collagen I in carbon tetrachloride-induced mice. Then we found that YD inhibited the level of miR-155, which plays an important role in inflammation and liver fibrosis. Bioinformatics analysis and luciferase reporter assay indicate that Casp12 is a new target of miR-155. We demonstrate that YD significantly decreases the contents of inflammatory cytokines and suppresses the NF-κB signaling pathway. Further studies show that transfection of the miR-155 mimic in RAW264.7 cells partially reversed the YD-mediated CASP12 upregulation, the downregulated levels of inflammatory cytokines, and the inactivation of the NF-κB pathways. Collectively, our study indicates that YD reduces inflammation through the miR-155–Casp12–NF-κB axis during liver fibrosis and provides a promising therapeutic candidate for hepatic fibrosis.
Association Between Plant and Animal Protein Intake and Overall and Cause-Specific Mortality
Authors: Jiaqi Huang, Linda M. Liao, Stephanie J. Weinstein, Rashmi Sinha, Barry I. Graubard, Demetrius Albanes
Journal: JAMA Internal Medicine (2020)

<h3>Importance</h3> Although emphasis has recently been placed on the importance of high-protein diets to overall health, a comprehensive analysis of long-term cause-specific mortality in association with the intake of plant protein and animal protein has not been reported. <h3>Objective</h3> To examine the associations between overall mortality and cause-specific mortality and plant protein intake. <h3>Design, Setting, and Participants</h3> This prospective cohort study analyzed data from 416 104 men and women in the US National Institutes of Health–AARP Diet and Health Study from 1995 to 2011. Data were analyzed from October 2018 through April 2020. <h3>Exposures</h3> Validated baseline food frequency questionnaire dietary information, including intake of plant protein and animal protein. <h3>Main Outcomes and Measures</h3> Hazard ratios and 16-year absolute risk differences for overall mortality and cause-specific mortality. <h3>Results</h3> The final analytic cohort included 237 036 men (57%) and 179 068 women. Their overall median (SD) ages were 62.2 (5.4) years for men and 62.0 (5.4) years for women. Based on 6 009 748 person-years of observation, 77 614 deaths (18.7%; 49 297 men and 28 317 women) were analyzed. Adjusting for several important clinical and other risk factors, greater dietary plant protein intake was associated with reduced overall mortality in both sexes (hazard ratio per 1 SD was 0.95 [95% CI, 0.94-0.97] for men and 0.95 [95% CI, 0.93-0.96] for women; adjusted absolute risk difference per 1 SD was −0.36% [95% CI, −0.48% to −0.25%] for men and −0.33% [95% CI, −0.48% to −0.21%] for women; hazard ratio per 10 g/1000 kcal was 0.88 [95% CI, 0.84-0.91] for men and 0.86 [95% CI, 0.82-0.90] for women; adjusted absolute risk difference per 10 g/1000 kcal was −0.95% [95% CI, −1.3% to −0.68%] for men and −0.86% [95% CI, −1.3% to −0.55%] for women; all<i>P</i> &lt; .001). The association between plant protein intake and overall mortality was similar across the subgroups of smoking status, diabetes, fruit consumption, vitamin supplement use, and self-reported health status. Replacement of 3% energy from animal protein with plant protein was inversely associated with overall mortality (risk decreased 10% in both men and women) and cardiovascular disease mortality (11% lower risk in men and 12% lower risk in women). In particular, the lower overall mortality was attributable primarily to substitution of plant protein for egg protein (24% lower risk in men and 21% lower risk in women) and red meat protein (13% lower risk in men and 15% lower risk in women). <h3>Conclusions and Relevance</h3> In this large prospective cohort, higher plant protein intake was associated with small reductions in risk of overall and cardiovascular disease mortality. Our findings provide evidence that dietary modification in choice of protein sources may influence health and longevity.
O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010
Authors: D. Ilson, J. Moughan, H. Safran, D. Wigle, T. Depetrillo, M. Haddock, T. Hong, L. Leichman, L. Rajdev, M. Resnick, L. Kachnic, S. Seaward, H. Mamon, D. Dian Pardo, C. Anderson, X. Shen, A. Sharma, A. Katz, J. Salo, K. Leonard, C. Crane
Journal: Annals of Oncology (2020)
Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208–16
Authors: Egesta Lopci, Massimo Lazzeri
Journal: European Urology (2020)
Abstract 16545: Medical Insurance Type and Team-Based Expert Care Affect All-Cause Mortality in Hypertrophic Cardiomyopathy Patients
Authors: Alexander Thomas, Nikolaos Papoutsidakis, Adriel Sumathipala, Xin Hu, Fangyong Li, Erica Spatz, Daniel Jacoby
Journal: Circulation (2018)

Introduction: The impact of team-based expert medical care in hypertrophic cardiomyopathy (HCM) has not been adequately examined. Hypothesis: We hypothesized that HCM patients with limited resource...
P-193 Safety, tolerability, and efficacy of total neoadjuvant therapy for adult patients with locally advanced high-risk rectal adenocarcinoma: Retrospective real-world data from South India
Authors: A. John, A. Joel, J. Georgy, A. Singh, M. Jesudasan, R. Mittal, T. Ram, J. Reddy, A. Chandramohan, R. Ninan, D. Masih, B. Yadav
Journal: Annals of Oncology (2020)
Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States
Authors: Nicolas A. Menzies, Meghan Bellerose, Christian Testa, Nicole A. Swartwood, Yelena Malyuta, Ted Cohen, Suzanne M. Marks, Andrew N. Hill, Anand A. Date, Susan A. Maloney, Sarah E. Bowden, Ardath W. Grills, Joshua A. Salomon
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Most U.S. residents who develop tuberculosis (TB) were born abroad, and U.S. TB incidence is increasingly driven by infection risks in other countries.Objectives: To estimate the potential impact of effective global TB control on health and economic outcomes in the United States.Methods: We estimated outcomes using linked mathematical models of TB epidemiology in the United States and migrants' birth countries. A base-case scenario extrapolated country-specific TB incidence trends. We compared this with scenarios in which countries achieve 90% TB incidence reductions between 2015 and 2035, as targeted by the World Health Organization's End TB Strategy ("effective global TB control"). We also considered pessimistic scenarios of flat TB incidence trends in individual countries.Measurements and Main Results: We estimated TB cases, deaths, and costs and the total economic burden of TB in the United States. Compared with the base-case scenario, effective global TB control would avert 40,000 (95% uncertainty interval, 29,000–55,000) TB cases in the United States in 2020–2035. TB incidence rates in 2035 would be 43% (95% uncertainty interval, 34–54%) lower than in the base-case scenario, and 49% (95% uncertainty interval, 44–55%) lower than in 2020. Summed over 2020–2035, this represents 0.8 billion dollars (95% uncertainty interval, 0.6–1.0 billion dollars) in averted healthcare costs and $2.5 billion dollars (95% uncertainty interval, 1.7–3.6 billion dollars) in productivity gains. The total U.S. economic burden of TB (including the value of averted TB deaths) would be 21% (95% uncertainty interval, 16–28%) lower (18 billion dollars [95% uncertainty level, 8–32 billion dollars]).Conclusions: In addition to producing major health benefits for high-burden countries, strengthened efforts to achieve effective global TB control could produce substantial health and economic benefits for the United States.
SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma
Authors: V. Chung, A. Alistar, B. George, K. Kim, H. Kindler, D. Oh, S. Allen, H. Barak, B. Ci, J. Lau, A. Retiere, C. Shemesh, V. Teichgräber, X. Zhang, C. Lopez
Journal: Annals of Oncology (2020)